INC Research Launches "Perspectives" Webinar Series Providing Insights from Key Industry Thought Leaders on the Latest Thinking in Clinical Research
(Thomson Reuters ONE) -
Upcoming Series includes Eight Sessions Focusing on Therapeutic Insights,
Emerging Issues in Clinical Development and the Latest on FSP Partnerships
Raleigh, NC, Aug. 13, 2012 - INC Research, LLC, a therapeutically focused
clinical research organization (CRO) with a Trusted Process(®) for delivering
reliable results, today announced the launch of its "Perspectives" webinar
series designed to bring together key industry experts and thought leaders to
share the latest insights and best practices on the many facets of clinical
research. INC Research thought leaders will participate in discussions along
with a well-rounded group of industry experts, to provide valuable and practical
knowledge on such topics as therapeutic insights on clinical trial design,
emerging issues in clinical development and the latest on Functional Service
Provider (FSP) partnerships.
"The 'Perspectives' series is designed to spotlight the latest developments and
best practices in clinical research today," said Alistair Macdonald, President,
Clinical Development Services, INC Research. "By sharing experiences on the
emerging and most impactful areas of clinical research, we will provide
practical information that attendees can incorporate in their day-to-day
activities, as well as key insights related to broader strategic issues. With
exclusive access to industry leaders, attendees will have a unique opportunity
to get answers to their most thought-provoking questions on issues that matter
most."
INC's "Perspectives" series kicks off Aug. 28 and includes eight one-hour
sessions, concluding mid-November with "Regulatory and Ethics Committees in the
United States: Perspectives on Pediatrics Clinical Trials." Further reinforcing
the Company's therapeutic focus, the webinar series features three therapeutic
sessions on wide-ranging topics, including "Early Phase Oncology Transitional
Studies," "Microbiology Operations in Infectious Disease Clinical Trials," and
"Recent Important Diabetes Studies - Implications for Clinical Practice."
To learn more about "Perspectives" or to register for the upcoming series, visit
www.incresearch.com/perspectives.
About INC Research, LLC
INC Research is a therapeutically focused clinical research organization with a
high-performance reputation for conducting global clinical development programs
of the highest integrity. Pharmaceutical and biotechnology companies look to INC
Research for a complete range of customized Phase I through Phase IV programs in
all therapeutic areasand innovative pediatric and women's health trials. The
Company's Trusted Process(®) methodology and therapeutic foresight lead
customers to more confident, better-informed drug and device development
decisions. INC Research is headquartered in Raleigh, NC. For more information,
please visit www.incresearch.com or follow us at (at)inc_research.
Contact: Lori Dorer, Media (513) 345-1685
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: INC RESEARCH, LLC via Thomson Reuters ONE
[HUG#1633608]
Unternehmensinformation / Kurzprofil:
Datum: 13.08.2012 - 20:23 Uhr
Sprache: Deutsch
News-ID 174156
Anzahl Zeichen: 3783
contact information:
Town:
Raleigh
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 146 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"INC Research Launches "Perspectives" Webinar Series Providing Insights from Key Industry Thought Leaders on the Latest Thinking in Clinical Research"
steht unter der journalistisch-redaktionellen Verantwortung von
INC RESEARCH, LLC (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
